Bayer's Upgraded Guidance Meets a Cash-Flow Reality Check as Broker Targets Diverge

Bayer's improved profit outlook has drawn fresh attention from analysts, but the more telling detail sits further down the cash-flow statement. Even after the company lifted its annual guidance on 3 November, it still expects free cash flow to remain negative for the year. That single line turns the recovery story into a test of delivery rather than a victory lap.

The question investors now face is straightforward: how much of the operational progress actually reaches the till? At Bayer the answer cuts both ways. Management projects higher operating earnings alongside a smaller cash outflow — the direction is right, but the expected level still warrants scrutiny.

Pharma carries the earnings story

In the third quarter of 2026, Bayer posted group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Reuters reported that better-than-expected performance in the pharmaceuticals division prompted the company to raise its earnings guidance.

That matters more than the simple sequence of good headlines. The pharma unit is already contributing to the improved planning, giving anyone judging Bayer on operational grounds a concrete reference point: the division now has to meet the higher bar it helped set.

Should investors sell immediately? Or is it worth buying Bayer?

Bayer lifted its forecast for the EBITDA margin before special items in pharmaceuticals to a range of 25 to 27 percent, up from its previous target. A higher expected margin puts the quality of earnings front and center — supportive for Bayer as long as actual profitability carries the raised ambition. Good news, in other words, must now be measured against an already improved plan.

At group level, the upgraded 2026 guidance for EBITDA before special items stands at EUR 9.8 billion to EUR 10.3 billion, so the bar has moved up across the whole company.

Two yardsticks, one verdict

Earnings and cash flow belong side by side in any assessment. The profit forecast shows the operating potential; the free cash flow forecast shows how far the financial improvement extends on Bayer's own planning. On that measure, management expects minus EUR 1.5 billion to minus EUR 0.5 billion — better than before, yet negative across the entire range.

Here lies the limitation of the upbeat earnings narrative. The improved plan points to progress, provided Bayer keeps the expected outflow in check. Anyone weighing the operational recovery should give cash flow the same weight as margins.

Deutsche Bank lifts its target

The more eye-catching broker move came from Deutsche Bank, which raised its price target for Bayer from EUR 60 to EUR 65 while reaffirming its buy rating. The weightier message, though, sits in the higher earnings estimates: the pharma division is supplying operating arguments for a friendlier valuation.

Deutsche Bank lifted its forecast for adjusted EBITDA in fiscal 2026 by roughly 3 percent to EUR 10.060 billion, with pharmaceuticals providing the impetus. Its expectations for Crop Science, by contrast, were trimmed slightly. That divergence is what makes the analysis useful — a targeted re-rating of earnings power, contingent on pharma sustaining its improvement and offsetting weakness in agriculture. Bayer must deliver above all where analysts now expect more.

Analyst Virginie Boucher-Ferte also raised her EBITDA and earnings-per-share estimates for 2027 and 2028 by about 3 percent each, so the more confident view extends well beyond the current fiscal year. A higher valuation rests on firmer ground when expected profits climb across several years, provided the improved outlook shows up in actual trading.

The operating evidence

The third-quarter figures show how much ground the division has already covered. Pharma EBITDA rose 23.6 percent, with the margin reaching 27.6 percent. That gives the positive assessment operational substance — and the real prize for Bayer would be durable growth from key medicines translating into higher profitability, the very test that rising group earnings expectations must pass.

Nubeqa lifted revenue by 58.3 percent in currency-adjusted terms to around EUR 1 billion, while Kerendia added 64.9 percent. That momentum supports the pharma unit as long as it reliably generates additional earnings, and the trajectory of products already growing deserves at least as much attention as hopes pinned on future medicines. It offers a concrete yardstick for whether Bayer can meet its more optimistic profit assumptions.

Bayer at a turning point? This analysis reveals what investors need to know now.

The financial counter-check

On the financial side, the picture is weaker so far. Bayer recorded a net loss of EUR 672 million in the third quarter of 2026 and free cash flow of minus EUR 293 million. Rising adjusted earnings strengthen the company above all when they bring financial relief with them; a better cash flow would lend the operational advances more weight and improve the basis for further debt reduction.

Net financial debt stood at EUR 31.1 billion at the end of September 2026, a figure that already factors in EUR 3 billion in proceeds from the Apollo transaction. The deal has provided relief, but a durably sturdier balance sheet will depend heavily on how free cash flow develops and on the ongoing business contributing its share.

Jefferies stays on the sidelines

Jefferies offered a cooler read on the same day. Analyst Michael Leuchten called the US approval of Asundexian in line with expectations, while writing that the risk to Bayer's pharmaceutical pipeline had fallen considerably as a result. The approval adds another building block to the pharma story, though the valuation will hinge on the economic contribution Bayer extracts from it — a lower development risk strengthens the outlook only if it produces operating progress.

Jefferies reiterated its hold rating with a price target of EUR 48.50. At EUR 57.16, the stock trades above that mark, leaving the two brokers on opposite sides of the current price.

The upshot is a matter of emphasis. Bayer has strengthened its operating position with the improved guidance, and Deutsche Bank's higher valuation is well grounded operationally as long as pharma strength persists. The decisive next test, however, lies in the cash flow: the story earns more confidence when higher profit estimates turn into sturdier financing power, with higher pharma earnings and an improved cash flow advancing together.

Ad

Bayer Stock: New Analysis - 10 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...